Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.

Abstract

PURPOSE Cigarette smoking induces CYP1A1/1A2 and is hypothesized to alter erlotinib pharmacokinetics. This study aimed to determine the maximum tolerated dose (MTD) of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients who smoke and compare the pharmacokinetics of erlotinib at the MTD in current smokers with 150 mg. PATIENTS AND METHODS… (More)
DOI: 10.1200/JCO.2008.19.3995

Topics

  • Presentations referencing similar topics